Blogs & News
Cell Therapy Group & BioBusiness.TV team up to cover the
Phacilitate Cell & Gene Therapy Forum 2009
Lee Buckler reviews some of the notable activity in Cell Therapy for the year 2008 (pharma’s interest, late stage companies, financing trends), and gives and outlook for the year 2009 (late stage companies, financing for struggling companies, role of the Obama administration). Watch Program »

Harvard Stem Cell Institute (HSCI) Executive Director Brock Reeve commented “Harvard is stepping into the cell therapy funding gap with a mission for academic research to get to patients.” Reeve explains the functioning of the Harvard Stem Cell Institute (HSCI). The HSCI is looking to make the bedside-tobench
and bench-to-bench loop in a way that unequaled anywhere, with the university, its 11 affiliated hospitals, drawing resources from the various schools (law, business, government, divinity). Reeve also comments on the HSCI partnership with GSK, as well as the other relationships they are seeking and
building at the moment. Watch Program »

Roche Global Alliance Director, Dr. Alain Vertes presents the interest of big pharma in the cell therapy. He highlights the main points of his panel presentation: (1) cell therapy is not a passing fad (2) cells are not just transplants, they can also be drugs (3) what paradigm shifting applications will be for cell
therapy (4) how intellectual property will be protected (5) why cell therapy has potential for stunning efficacy and low risk of side effects. Watch Program »

ERA Consulting Director of Regulatory Affairs, Christopher Bravery comments on US and EU Regulatory Synergies, and on the EMEA Committee for Advanced Therapies. Bravery explains the mission of the new committee for advanced therapies of the EMEA, and its impact on the development of cell therapy in Europe. Bravery also reflects on the similarity between US and European regulatory environments, and the importance of considering that in planning pivotal studies. Finally Bravery gives his definition of Cell Therapy and explains the business of ERA Consulting. Watch Program »

BioBusiness.TV released for the first time programs in it’s “Mash Up” series. BioBusiness.TV polls audiences on specific questions (in a video interviews format), then mashes up the responses in a fun, lively, and informative way that is meant to reveal the aggregate perception of a group. The questions asked were :
• How Would You Define Cell Therapy?
• Are We Going to See New Cell Therapy Products in the Next 2-3 Years?
• How Many Cell Therapy Products Are On the Market Today?
• What Are Some of the Exciting Things Happening in Cell Therapy?

In it’s “60sec Pitches” - where less is more, and company executives have 60
seconds to give a presentation, a general overview, and make a good first
impression - BioBusiness.TV releases videos for the following companies :
• Maxcyte, Inc
• Florida Biologix
• Athersys, Inc.
___________________________________________________________



Cell Therapy Group Challenges Industry to Support Non-Profit Sector

the Cell Therapy Group has committed financial support in 2009 to the cell therapy industry's leading
non-profit organization, ISCT (the International Society for Cellular Therapy) and challenges its corporate
peers to do the same.

Mountain View, CA -- (January 2, 2009) The Cell Therapy Group (www.celltherapygroup.com) announced today it hasmade the financial commitment to support the International Society for Cellular Therapy (ISCT) in 2009 through its corporate membership program.

The Group issued a challenge to all its corporate colleagues in the cell therapy and regenerative medicine
sector to do the same. "ISCT is the leading non-profit organization in the sector," stated Cell Therapy
Group principle consultant, R. Lee Buckler. "It is important - even more so in these tough financial times -
that we support the organizations that facilitate and support the growth of the industry."

As part of a payback to companies who support the organization, each company participating in corporate
membership of ISCT will be entitled to name a representative to the organization's Commercialization
Committee, chaired by Cell Therapy Group's Lee Buckler.

"In 2009, we intend to grow on the strengths of the Commercialization Committee to make it a core
activity hub for those interested in pooling resources and commitments to do for the maturation of the cell
therapy industry what each company cannot do individually," states Buckler.

"To build a vibrant, mature industry in the cell therapy sector, we need the active commitment and
collaboration of stakeholders from government, academics, non-profits, and companies," Buckler
concludes. "ISCT provides the infrastructure within this is already taking place and we need to continue to
build on its strengths for the benefit of both the industry its serves and the patients who will ultimately
benefit from the therapies we intend to bring to market".

Cell Therapy Group
Cell Therapy Group (CTG) is the consulting business of its founder Lee Buckler. CTG is the consultancy
for the commercial side of the cell therapy and regenerative medicine sector serving therapeutic, device,
and reagent companies, investors, publishers, other consultants, etc with marketing, business development, market analysis & research, sales & lead generation, advertising, project management, business & strategic planning, and other types of services related to the commercialization of cell therapies, regenerative medicine products, and ancillary support products and services. For more information see www.celltherapygroup.com.

ISCT
ISCT is the global forum and resource for developing and supporting innovative cellular therapies through
communication, education, and training, thus furthering clinical based investigation for the benefit of
patients. Established in 1992, the Society provides a global forum for Communication, education and
training; Performance of collaborative scientific studies; Development and validation of standardized
technology; Representation of the membership to other professional organizations and regulatory and
governmental bodies.  For more information see www.celltherapy.org.

___________________________________________________________

Cell Therapy Group Consultant Appointed to Regenerative Medicine Editorial Board
Regenerative Medicine appoints cell therapy industry consultant Lee Buckler to its editorial board.

Vancouver, BC (PRWEB) August 27, 2008 -- The Cell Therapy Group (http://www.celltherapygroup.com/) announced today the appointment of its principle consultant, R. Lee Buckler, to the Editorial Board of the journal Regenerative Medicine.

Published by Future Medicine, Regenerative Medicine has become a premier journal for a fast growing community of specialists addressing the important challenges and advances in the commercializing of cell therapy research and regenerative medicine.

Under the aegis of Dr. Chris Mason who heads the Regenerative Medicine Bioprocess Group in the Advanced Centre for Biochemical Engineering at University College London (UCL), the journal features an editorial board of over 70 leading international experts drawn from the leading forces in industry and academia.

Mr. Buckler has served many capacities in the regenerative medicine sector to-date including Executive Director of the International Society for Cellular Therapy (ISCT), Operations Manager of Malachite Management, Founder and Editor-in-Chief of Cell Therapy News, business development and marketing communications at Progenitor Cell Therapy and DomaniCell, and communications at Amorcyte, Inc. Lee also served on the Editorial Advisory Board of BioProcess International. Lee heads business and commercial consulting services at the Cell Therapy Group and also blogs at CellTherapyBlog.com (http://www.celltherapyblog.com/).

"I am pleased to have an opportunity to contribute in this way," says Lee, "to an industry poised - I believe in the short term - to bring significant, new therapeutic and commercial successes to market. The journal, Regenerative Medicine, in addition to great science offers a unique focus on commercialization and industry challenges that will be critical to the success of this field. It is on those issues for the cell therapy sector that I look to contribute to the journal and the industry as a whole."

the Cell Therapy Group

Cell Therapy Group (CTG) is a consultancy for the commercial side of the cell therapy and regenerative medicine sector serving therapeutic, device, and reagent companies, investors, publishers, and other consultants with marketing, communications, business development, market analysis & research, management, strategic planning and other types of services related to the commercialization of cell therapies, regenerative medicine products, and ancillary support products and services. For more information, see CellTherapyGroup.com (http://www.celltherapygroup.com/).

Regenerative Medicine

Indexed on MEDLINE and ISI Science Citation Index, Regenerative Medicine was recently recognized by The Association of Learned and Professional Society Publishers as joint winner of the 2006 ALPSP/Charlesworth Award for Best New Journal. This prestigious international award is presented annually to the best new journal across a wide range of disciplines. For more info, see www.futuremedicine.com/loi/rme.

Copyright . Cell Therapy Group. All rights reserved.